Wolverine Trading, LLC Avadel Pharmaceuticals PLC Transaction History

Wolverine Trading, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$9.64 - $14.59 $57,685 - $87,306	5,984 Added 40.45%	20,776 $293,000
Q3 2023 Nov 15, 2023	SELL	$10.3 - $15.99 $17,108 - $26,559	-1,661 Reduced 10.1%	14,792 $152,000
Q2 2023 Aug 23, 2023	BUY	$8.48 - $16.48 $139,521 - $271,145	16,453 New	16,453 $271,000
Q1 2021 May 14, 2021	SELL	$6.61 - $10.07 $10,754 - $16,383	-1,627 Reduced 13.67%	10,274 $91,000
Q4 2020 Feb 12, 2021	SELL	$5.03 - $7.95 $95,368 - $150,732	-18,960 Reduced 61.44%	11,901 $80,000
Q1 2020 May 11, 2020	BUY	$4.06 - $10.64 $125,295 - $328,361	30,861 New	30,861 $269,000
Q4 2019 Feb 12, 2020	SELL	$3.34 - $7.7 $35,888 - $82,736	-10,745 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$1.92 - $4.47 $27,507 - $64,041	-14,327 Reduced 57.14%	10,745 $46,000
Q2 2019 Aug 20, 2019	BUY	$1.09 - $3.19 $12,314 - $36,040	11,298 Added 82.02%	25,072 $72,000
Q4 2017 Feb 14, 2018	BUY	$8.03 - $11.25 $110,605 - $154,957	13,774	13,774 $113,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $661M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Trading, LLC with notifications on news.